TYPE II DIABETES MELLITUS AND MANAGEMENT OF ISOLATED HYPERGLYCEMIA: A REVIEW

Authors

  • JUAN DIEGO CAYO TELLO Hospital Básico Yerovi Mackuart, Salcedo, Ecuador.
  • DIANA ELIZABETH SÁNCHEZ MORETTA Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
  • GABRIELA JENNIFER VARGAS HERNÁNDEZ Facultad de Ciencias Médicas, Universidad Central del Ecuador, Quito, Ecuador.
  • LUIS SANTIAGO HERNÁNDEZ MEDINA Médico Residente de Cirugía en Hospital de Especialidades Crehvital, Ambato, Ecuador.

DOI:

https://doi.org/10.22159/ijhs.2022.v10i1.44968

Keywords:

Type II Diabetes mellitus, Insulin Resistance, Hyperglycemia, Hyperinsulinism, Polydipsia, Polyuria, Polyphagia

Abstract

Type II Diabetes mellitus (T2DM) is the most common of two types of Diabetes disease. T2DM is a metabolic disease characterized mainly by insulin resistance, reduction of insulin secretion, and hyperglycemia. T2DM is a major public health cause of concern not only by the increase in morbidity and mortality associated with patients with the disease, but also by the significant reduction in quality of life and productivity among the economically active population. Isolated hyperglycemia refers to patients with T2DM with normal fasting plasma glucose and no ketoacidosis. With the rise of T2DM and the presence of hidden symptoms, it is vital to determine a diagnostic sequence, blood-glucose control with sulfonylureas or insulin, and diet and exercise.

References

Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 diabetes: Demystifying the global epidemic. Diabetes 2017;66:1432-42.

International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019. Available from: https://www.diabetesatlas.org [Last accessed on 2020 Sep 03].

Fowler M. Hyperglycemic crisis in adults: Pathophysiology, presentation, pitfalls, and prevention. Clin Diabetes 2009;27:19-23.

Nathan DM, Bennett PH, Crandall JP, Edelstein SL, Goldberg RB, Kahn SE, et al. Does diabetes prevention translate into reduced long-term vascular complications of diabetes? Diabetology 2019;62:1319-28.

Murillo LJ. Medicina de Urgencias Y Emergencias. 6th ed. Netherlands: Elsivier; 2018.

American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26:S33-50.

Rodriguez-Gutierrez R, Gonzalez-Gonzalez JG, Zuñiga-Hernandez JA, McCoy RG. Benefits and harms of intensive glycemic control in patients with Type 2 diabetes. BMJ 2019;367:l5887.

International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2019.

International Diabetes Federation. Diabetes by Region. IDF Diabetes Atlas. Vol. 9. Brussels, Belgium: International Diabetes Federation; 2019.

World Health Organization. Global Report on Diabetes. Geneva: World Health Organization; 2016.

International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels, Belgium: International Diabetes Federation; 2017. Available from: https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf [Last accessed on 2022 Mar 07].

International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327-34.

American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2017;40:S11-24.

Pozzilli P, Strollo R, Bonora E. One size does not fit all glycemic targets for Type 2 diabetes. J Diabetes Investig 2014;5:134-41.

Stumvoll M, Goldstein B, Haeften T. Type 2 diabetes: Pathogenesis principles and therapy. Lancet 2016;365:1333-46.

American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care 2021;44:S15-33.

Engelgau MM, Narayan KM, Herman WH. Screening for Type 2 diabetes. Diabetes Care 2000;23:1563-80.

Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1985;61:917-25.

Robertson P, Nathan D, Mulder J. Pathology diabetes Type 2. Lancet 2021;21:6275.

Pan A, Sun Q, Bernstein AM, Manson JE, Willett WC, Hu FB. Changes in red meat consumption and subsequent risk of Type 2 diabetes mellitus: Three cohorts of US men and women. JAMA Intern Med 2013;173:1328-25.

Emerging Risk Factors Collaboration; Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.

Merino J, Udler M, Leong A, Meigs J. Una década de contribuciones genéticas y metábolicas a la prediccion del riesgo de diabetes tipo 2. Curr Diab 2017;17:135.

Davies MJ, D’Alessio DA, Fradkin J, Kernan W, Mathieu CH, Mingrone G, et al. Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2018;41:2669-701.

Asociación Latinoamerica de Diabetes. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Tipo 2. Asociación Latinoamerica de Diabetes; 2019.

Huang T, Wang T. Asociación del peso al nacer con diabetes tipo 2 y rasgos glucémicos: Un estudio de aleatorización mendeliana. JAMA Netw Open 2019;2:e1910915. https://doi.org/10.1001/jamanetworkopen.2019.10915.

Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009;57:495-9.

Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. J. Parent Ent Nut 2004;28:364-71.

Thambisetty M, Metter EJ, Yang A, Dolan H, Marano C, Zonderman AB, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the baltimore longitudinal study of Aging. JAMA Neurol 2013;70:1167-72.

Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-80.

Yahia N, Brown CA, Snyder E, Cumper S, Langolf A, Trayer C, et al. Prevalence of metabolic syndrome and its individual components among Midwestern University students. J Commun Health 2017;42:674-87.

Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, da Silva Dias D, et al. Insulin resistance: An additional risk factor in the pathogenesis of cardiovascular disease in Type 2 diabetes. Heart Fail Rev 2016;21:11-23.

Arner P. Insulin resistance in Type 2 diabetes: Role of fatty acids. Diabetes Metab Res Rev 2002;18:S5-9.

Yki-Järvinen H. Glucose toxicity. Endocr Rev 1992;13:415-31.

Hirahatake KM, Meissen JK, Fiehn O, Adams SH. Comparative effects of fructose and glucose on lipogenic gene expression and intermediary metabolism in HepG2 liver cells. PLoS One 2011;6:e26583.

Rauchman MU, Wasserman JC, Cohen DM, Perkins DL, Hebert SC, Milford E, et al. Expression of GLUT-2 cDNA in human B lymphocytes: Analysis of glucose transport using flow cytometry. Biochem Biophys Acta (BBA)-Biomembr 1992;1111:231-8.

Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting plasma glucose and glycosylated hemoglobin: Potential for false-positive diagnoses of Type 2 diabetes using new diagnostic criteria. JAMA 1999;281:1203-10.

Andersson DK, Lundblad E, Svärdsudd K. A model for early diagnosis of Type 2 diabetes mellitus in primary health care. Diabetes Med 1993;10:167.

Meigs JB, Cupples LA, Wilson PW. Parental transmission of Type 2 diabetes: The Framingham offspring study. Diabetes 2000;49:2201.

Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004;279:42351-4.

Boland BB, Rhodes CJ, Grimsby JS. The dynamic plasticity of insulin production in β-cells. Mol Metabol 2017;6:958-73.

Moin AS, Butler AE. Alterations in beta cell identity in Type 1 and Type 2 diabetes. Curr Diabet Rep 2019;19:83.

Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001;50:S154-9.

Umpierrez GE, Murphy MB, Kitabchi AE. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. Diabetes Specr 2002;15:28-36.

Volek JS, Sharman MJ, Love DM, Avery NG, Scheett TP, Kraemer WJ, et al. Body composition and hormonal responses to a carbohydrate-restricted diet. Metabolism 2002;51:864-70.

NHLBI Obesity Education Initiative-Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report, September; 1998. Available from: https://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf [Last accessed on 2012 Apr 12].

Manna TD, Steinmetz L, Campos PR, Farhat SC, Schvartsman C, Kuperman H, et al. Subcutaneous use of a fast-acting insulin analog: An alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005;28:1856-61.

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-43.

Diabetes Control and Complications Trial Research Group; Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra rapid-acting inhaled insulin improves glucose control in patients with Type 2 diabetes mellitus. Endoc Pract 2021;27:449-54.

Woolfson AM. An improved method for blood glucose control during nutritional support. JPEN J Parent Ent Nut 1981;5:436-40.

Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham study. Am Heart J 1991;121:586-90.

Published

22-07-2022

How to Cite

TELLO, J. D. C., MORETTA, D. E. S., HERNÁNDEZ, G. J. V., & HERNÁNDEZ MEDINA, L. S. (2022). TYPE II DIABETES MELLITUS AND MANAGEMENT OF ISOLATED HYPERGLYCEMIA: A REVIEW. Innovare Journal of Health Sciences, 10(1), 1–4. https://doi.org/10.22159/ijhs.2022.v10i1.44968

Issue

Section

Review Article(s)